DPP-IV (Dipeptidyl Peptidase-IV)

Dipeptidyl Peptidase-IV (DPP-IV), also known as CD26, is a ubiquitously expressed serine exoprotease that cleaves dipeptides from the N-terminus of proteins containing a penultimate proline or alanine residue. In metabolic biology, DPP-IV's most clinically consequential substrates are the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), both of which are rapidly inactivated by DPP-IV cleavage within minutes of entering the circulation.

Why it matters in peptide research

The brief circulatory half-life of native GLP-1 — typically under two minutes — is almost entirely attributable to DPP-IV degradation. This creates a fundamental pharmacological problem: a peptide with potent insulinotropic, satiety-inducing, and gastric-emptying-slowing properties cannot be administered as an unmodified native sequence and achieve meaningful systemic exposure. This constraint drove two parallel drug-development strategies: DPP-IV inhibitor drugs (gliptins), which block the enzyme and extend endogenous GLP-1 survival, and DPP-IV-resistant GLP-1 analogues, which incorporate structural modifications at the enzyme's cleavage site.

The DPP-IV resistance strategy is central to understanding modern incretin-based peptides. GLP-1 analogues such as semaglutide introduce an Aib (aminoisobutyric acid) residue or amino acid substitution at position 2 — the DPP-IV cleavage site — combined with fatty-acid conjugation to extend half-life further via albumin binding. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, similarly incorporates N-terminal modifications and a C20 fatty-diacid conjugate to achieve once-weekly dosing by evading both DPP-IV cleavage and renal clearance.

For researchers, DPP-IV is also relevant as a marker: CD26/DPP-IV surface expression is used as a T-cell activation marker and is elevated on certain cancer cells, giving the enzyme a broader biological significance beyond metabolic regulation.

Peptides / stacks that act on this

• Tirzepatide — dual GIP/GLP-1 receptor agonist engineered with DPP-IV-resistant N-terminal modifications and fatty-acid conjugation to achieve once-weekly clinical dosing

Common misconceptions

"DPP-IV inhibitors" (gliptins) and "GLP-1 receptor agonists" are often conflated in lay discussions because both affect GLP-1 activity. They work by entirely different mechanisms: gliptins prevent enzymatic degradation of endogenous GLP-1 (modest effect), while GLP-1 receptor agonists are DPP-IV-resistant synthetic peptides that directly activate the receptor at pharmacological concentrations (much larger effect).